Jonathan F. Anker

Oncology
1 Gustave L Levy Pl
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

External control arms can validate treatment efficacy in single-arm studies.

External control arms can validate treatment efficacy in single-arm studies.

Journal: Journal of the National Cancer Institute
Published: March 24, 2026

Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer.

Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer.

Journal: Cancer research communications
Published: February 20, 2026

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Journal: Cancer discovery
Published: October 09, 2025

Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors.

Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors.

Journal: Clinical genitourinary cancer
Published: February 11, 2025

Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.

Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.

Journal: European urology
Published: January 29, 2025

A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.

A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.

Journal: Cancers
Published: November 25, 2024

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial.

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial.

Journal: Nature cancer
Published: August 15, 2024

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.

Journal: Cancer immunology research
Published: July 09, 2024

Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.

Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 21, 2024

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.

Journal: Journal for immunotherapy of cancer
Published: August 04, 2023

From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.

From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.

Journal: Cells
Published: November 01, 2021

Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.

Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.

Journal: Translational lung cancer research
Published: September 21, 2020
Showing 1-12 of 27

Last Updated: 09/26/2026